News
Public · Published
Cantor Fitzgerald initiates coverage of Spero Therapeutics with Overweight rating, $6 price target
Cantor Fitzgerald began covering Spero Therapeutics stock with a rating of Overweight and a $6.00 price target. That target implies an upside of 426.3% from the October 27 close of $1.14.
Published:
Updated:
What happened
Cantor Fitzgerald began covering Spero Therapeutics stock with a rating of Overweight and a $6.00 price target. That target implies an upside of 426.3% from the October 27 close of $1.14.
Confirmed
Global impact / market context
A broker rating can pull investor attention toward a small biotech stock, which means a research note may change how much money flows in or out. The size of the implied gain shows how far the analyst's view sits from the recent share price.
Analyst inference
The note ties its case to SP001, a monoclonal antibody, which means an engineered antibody medicine, aimed at IgG4-related disease. It argues the stock looks cheap compared with estimated peak sales above $1 billion, so the call rests on future drug revenue rather than current profits.
Analyst inference
What to watch
- Cantor's targets include peak sales estimates exceeding $1 billion for SP001 and other candidates, so watch whether later company updates support or undercut those sales projections. Confirmed
- Track trial progress and regulatory steps for SP001 in IgG4-related disease, because delays or weak results would challenge the analyst's case for improved efficacy and safety. Proposed
- Watch whether other analysts start coverage or revise views on Spero, since wider agreement or disagreement can shift investor positioning and the gap between the share price and the $6.00 target. Analyst inference
Evidence
- Original source link unavailable